Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2024-03-26 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于2021年限制性股票激励计划首次授予部分第二个归属期及预留授予部分第一个归属期归属结果公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the results of the vesting of restricted stock awards under the company's 2021 restricted stock incentive plan. It includes information about the number of shares vested, the decision-making process, the list of recipients, stock source, transfer restrictions, and verification by an accounting firm. It also mentions the completion of share registration with the securities registration authority. The document is not a full annual or interim financial report, nor is it a simple announcement of a report's publication. It is a formal disclosure related to stock incentive plan vesting results, which is a type of capital/financing update concerning equity awards and share registration. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-03-26 Chinese
圣湘生物科技股份有限公司第二届监事会2024年第一次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the first extraordinary meeting of the second Supervisory Board of the company in 2024. It details the meeting attendance, the agenda items discussed, and the voting results on matters related to adjustments in the restricted stock incentive plan, approval of stock vesting conditions, and cancellation of unvested restricted stocks. The document references compliance with relevant laws and regulations and mentions that detailed announcements are published separately on the stock exchange website. The document is short (1693 characters) and serves as an official announcement of board decisions rather than a full report or detailed financial disclosure. It does not contain financial statements or detailed management discussion but rather governance-related resolutions. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2024-03-08 Chinese
西部证券股份有限公司关于圣湘生物科技股份有限公司2023年度日常关联交易确认及预计2024年度日常关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a sponsoring securities company (西部证券股份有限公司) regarding the confirmation of daily related-party transactions for the year 2023 and the forecast for 2024 for 圣湘生物科技股份有限公司. It includes extensive financial data, transaction details, related party descriptions, and compliance with regulatory rules. The document is not a brief announcement but a substantive report with financial figures and analysis related to related-party transactions. It does not fit categories like Annual Report (10-K) or Interim Report (IR) since it focuses specifically on related-party transactions and their confirmation and forecast. It is not a regulatory filing or announcement but a formal audit or review opinion on related-party transactions, which aligns with the Audit Report / Information (AR) category. Therefore, the best classification is AR with high confidence. FY 2023
2024-03-08 Chinese
圣湘生物科技股份有限公司独立董事关于第二届董事会2024年第二次临时会议相关事宜的独立意见
Board/Management Information Classification · 90% confidence The document is an independent opinion from the independent directors of a company regarding the confirmation of related party transactions for the year 2023 and the forecast for 2024. It references compliance with laws and company articles but does not contain financial statements or detailed financial data. It is a governance-related document expressing independent directors' views on board matters, specifically related to a board meeting and related party transactions. This fits best under Board/Management Information (MANG) as it relates to board meeting matters and independent directors' opinions on company governance issues.
2024-03-08 Chinese
圣湘生物科技股份有限公司关于作废部分已授予尚未归属的限制性股票的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 圣湘生物科技股份有限公司 regarding the cancellation of certain granted but unvested restricted shares under a 2021 restricted stock incentive plan. It details board and supervisory meetings, approvals, legal opinions, and the impact of the cancellation on the company. The content focuses on corporate governance and equity incentive plan adjustments rather than financial results or earnings. The document length is 3689 characters, which is relatively short and primarily an announcement of a corporate action related to stock incentives. It does not contain financial statements or detailed financial analysis. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about stock incentive plan changes and cancellations, not a full report or financial statement.
2024-03-08 Chinese
圣湘生物科技股份有限公司关于2021年限制性股票激励计划首次授予部分第二个归属期及预留授予部分第一个归属期符合归属条件的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the 2021 restricted stock incentive plan of 圣湘生物科技股份有限公司. It includes information about the stock grant quantities, vesting periods, performance conditions, board and supervisory approvals, and legal opinions. The content focuses on the conditions for stock vesting, the approval process by the board and shareholders, and the fulfillment of vesting conditions for certain periods. It is not a financial report, earnings release, or audit report. It is also not a general regulatory filing or a report publication announcement since it contains substantive information about the stock incentive plan and its implementation. The document is an announcement about the vesting conditions and approvals related to a stock incentive plan, which fits best under the category of Capital/Financing Update (CAP), as it relates to equity incentives and share-based compensation plans, which affect the company's capital structure and financing arrangements.
2024-03-08 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.